zimberelimab
3 products
13 abstracts
Abstract
ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).Org: David Geffen School of Medicine at UCLA, University of California, Los Angeles, Seoul National University Hospital, Korea University Anam Hospital, Korea University College of Medicine,
Abstract
Phase I/II study of stereotactic radiation and sacituzumab govitecan with zimberelimab in the management of metastatic triple negative breast cancer with brain metastases.Org: H. Lee Moffitt Cancer Center and Research Institute, Department of Neurosurgery, Prince of Wales Hospital,
Abstract
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.Org: University of Wisconsin, Carbone Cancer Center, Madison, WI, Wigen Biomedicine Technology (Shanghai), University of Wisconsin Carbone Cancer Center,
Abstract
VELOCITY-Lung substudy-03: A phase 2 study of neoadjuvant domvanalimab (dom)+zimberelimab (zim)+chemotherapy (chemo) or zim+chemo followed by adjuvant dom+zim or zim in patients with resectable stage II-III non-small cell lung cancer (NSCLC).Org: Fort Wayne Medical Oncology and Hematology, Christian Hospital, University Hospitals Birmingham NHS Foundation Trust, Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS), Shaare Zedek Medical Center,
Abstract
Real-world data of a regimen containing zimberelimab in the treatment of recurrent and metastatic cervical cancer.Org: Medical Affairs Department, Guangzhou Gloria Biosciences Co. Ltd.,
Abstract
Zimberelimab combined with concurrent chemoradiotherapy for patients with locally advanced cervical cancer: Early results of efficacy and safety.Org: Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Fudan University Zhongshan Hospital,
Abstract
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.Org: Stanford Cancer Center, Portuguese Oncology Institute of Porto, Porto, Portugal, The Kinghorn Cancer Centre, CUF Instituto de Oncologia, Macquarie University,
Abstract
STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.Org: Moffitt Cancer Center, Samsung Medical Center, Sarah Cannon Research Institute/Tennessee Oncology, Gilead Sciences, Inc., Arcus Biosciences,
Abstract
STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.Org: Mass General Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Arcus Biosciences, Gilead Sciences, Inc., Memorial Sloan Kettering Cancer Center,
Abstract
ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.Org: Arcus Biosciences, Gilead Sciences, Inc.,
Abstract
TROPHY-U-01 Cohort 4 (C4): Sacituzumab govitecan (SG) in combination with cisplatin (cis) as first-line (1L) therapy, followed by maintenance avelumab plus (+) SG or zimberelimab (zim) + SG in patients (pts) with treatment (Tx)-naïve metastatic urothelial cancer (mUC).Org: Gilead Sciences, Inc., Institut de Cancérologie Strasbourg Europe,
Abstract
VELOCITY-Lung: A phase (Ph) 2 study evaluating safety and efficacy of domvanalimab (dom) + zimberelimab (zim) + sacituzumab govitecan (SG), or etrumadenant (etruma) + dom + zim, or etruma + zim in patients (pts) with treatment-naïve metastatic non-small cell lung cancer (mNSCLC).Org: Virginia Cancer Specialists, Queen Mary Hospital, Chang Gung Medical Foundation-LinKou Branch, Rambam Health Care, St Barthlomew's Hospital,
Product
etrumadenant + zimberelimab